MedPath

University of Zurich

University of Zurich logo
🇨🇭Switzerland
Ownership
Private
Established
1833-04-29
Employees
5K
Market Cap
-
Website
http://www.uzh.ch

Clinical Trials

1.0k

Active:38
Completed:598

Trial Phases

6 Phases

Early Phase 1:10
Phase 1:41
Phase 2:73
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (646 trials with phase data)• Click on a phase to view related trials

Not Applicable
397 (61.5%)
Phase 4
92 (14.2%)
Phase 2
73 (11.3%)
Phase 1
41 (6.3%)
Phase 3
33 (5.1%)
Early Phase 1
10 (1.5%)

Magnetic Resonance Imaging-guided Online Adaptive Radiotherapy of Pelvic Lymph Node Metastases

Not Applicable
Recruiting
Conditions
Pelvic and Para-aortic Lymph Node Metastases
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
University of Zurich
Target Recruit Count
20
Registration Number
NCT07083648
Locations
🇨🇭

Zurich University Hospital, Department of Radiation Oncology, Zürich, Zurich, Switzerland

Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study

Not Applicable
Recruiting
Conditions
Parkinson Disease
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
University of Zurich
Target Recruit Count
40
Registration Number
NCT07082595
Locations
🇨🇭

University of Zurich, Zurich, Switzerland

Effects of Cerebrospinal Fluid Drainage on Cerebral Hemodynamics

Not Applicable
Not yet recruiting
Conditions
Acute Ischemic Stroke
First Posted Date
2025-07-09
Last Posted Date
2025-07-09
Lead Sponsor
University of Zurich
Target Recruit Count
30
Registration Number
NCT07056907
Locations
🇨🇭

University Hospital Zurich, Zurich, Switzerland

Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer

Not Applicable
Not yet recruiting
Conditions
Localized Prostate Adenocarcinoma
First Posted Date
2025-06-29
Last Posted Date
2025-07-04
Lead Sponsor
University of Zurich
Target Recruit Count
13
Registration Number
NCT07042256

Robotic-assisted Bronchoscopy Under Moderate Sedation With Propofol

Not Applicable
Not yet recruiting
Conditions
Lung Lesions
Robotic Assisted Bronchoscopy
Propofol
Bronchoscopy
Bronchoscopy Biopsy
First Posted Date
2025-06-05
Last Posted Date
2025-06-05
Lead Sponsor
University of Zurich
Target Recruit Count
30
Registration Number
NCT07006311
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 202
  • Next

News

Arcturus Therapeutics to Present Phase 2 Data for ARCT-810 mRNA Therapy in Rare Genetic Disorder

Arcturus Therapeutics will host a virtual presentation on June 30, 2025, featuring Phase 2 interim data for ARCT-810, an investigational mRNA therapeutic for ornithine transcarbamylase deficiency.

Phase 1/2 KEYMAKER-U02 Trial: Pembrolizumab Shows Manageable Safety Profile in Stage IIIB-D Melanoma

Neoadjuvant pembrolizumab, alone or combined with vibostolimab or gebasaxturev, demonstrated a manageable safety profile in stage IIIB-D melanoma patients, with 95% experiencing at least one adverse event.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.